ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FRNM / options
TRUP (63) ALHC (56) CSTL (62) LMRI (53) ⌘ Pro Terminal →

Freenome Inc. (FRNM) Options Positioning, Max Pain & Unusual Sweeps

$11.61 -6.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.44

Freenome Inc. (FRNM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.34B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FRNM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FRNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Freenome Inc. (NASDAQ: FRNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $11.61 (-6.97% 1D, market cap $1.34B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FRNM ranks #752 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FRNM compare to TRUP and ALHC in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), FRNM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.4%. By comparison, TRUP (Trupanion Inc.) holds a C grade (63/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B) and ALHC (Alignment Healthcare Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC 13.9%, cap $1.52B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FRNM?
▼

Per FRNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002017526), Freenome Inc. generated $8.3M in revenue (-77.9% YoY), $837.5K in net income, and -$864.7K in free cash flow against $92.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.44 (-1.44%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (5)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$18 Bull$10 Base$8 Bear
📬 FREE FRNM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FRNM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY FRNM SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 40.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$12.64+11.2% Next Q
Q2 (-2Q)
36
Grade E$14.06-7.3% Next Q
Q3 (-1Q)
34
Grade E$13.04-11% Next Q
Current
31
Grade E$11.61-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FRNM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FRNM currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.69) and Max Pain ($12.19) forces dealer call-delta covering toward $18.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FRNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FRNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (FRNM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for FRNM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FRNM)

  • ✓Walkthrough of FRNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FRNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.13%🛡️ HOLDING TREND SUPPORT
2026-11-03O $12.86H $12.86L $11.61C $11.61VOL 651.2K
RES: $19.98SUP: $11.64SMA50: $14.69SMA200: $12.51
$18.03$15.84$13.65$11.46$9.27RES $19.98SUP $11.64$11.612026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FRNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FRNM Butterfly Map → + Track FRNM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -77.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FRNM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FRNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FRNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FRNM)

Health Care Rank #752 of 1015 ⚔️ TRUP vs FRNM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FRNM vs. TRUP, ALHC, CSTL, LMRI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Freenome Inc. (FRNM) ranks #752 by composite RQD confidence (31/100, grade E) and #314 by equity capitalization ($1.34B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. TRUP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with FRNM at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FRNM ACTIVE
Freenome Inc.
E 31/100 — — -3.4% -6.97% $1.34B Benchmark Subject
TRUP
Trupanion Inc.
C 63/100 68.2x 16.1% 3.1% +2.06% $1.32B /trup-vs-frnm →
ALHC
Alignment Healthcare Inc.
D+ 56/100 — — 13.9% -3.71% $1.52B /alhc-vs-frnm →
CSTL
Castle Biosciences Inc.
C 62/100 — 79.4% -9.3% -5.97% $1.14B /cstl-vs-frnm →
LMRI
Lumexa Imaging Holdings Inc.
D+ 53/100 — — — -2.28% $1.10B /lmri-vs-frnm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002017526 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Freenome Inc. (FRNM) reported GAAP revenue of $8.3M (-77.9% vs. FY2024 revenue of $37.8M ) , GAAP net income of $837.5K, operating cash flow of -$864.7K, and free cash flow of -$864.7K . On the balance sheet, FRNM closed FY2025 with $92.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $8.3M $837.5K -$864.7K -$864.7K $92.8M —
FY2024 (FY) 2024-12-31 $37.8M $0 — — $89.9M —

3. FRNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FRNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Freenome Inc. (NASDAQ: FRNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $11.61 (-6.97% 1D, market cap $1.34B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FRNM ranks #752 in composite RQD confidence.

How does FRNM compare to TRUP and ALHC in the Health Care sector?

Within the Health Care sector (Medical Specialities), FRNM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.4%. By comparison, TRUP (Trupanion Inc.) holds a C grade (63/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B) and ALHC (Alignment Healthcare Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC 13.9%, cap $1.52B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FRNM?

Per FRNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002017526), Freenome Inc. generated $8.3M in revenue (-77.9% YoY), $837.5K in net income, and -$864.7K in free cash flow against $92.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FRNM trading relative to its 50-day, 200-day, and 52-week technical levels?

FRNM last traded at $11.61 (-6.97% on volume of 685,995 shares), positioning the stock -20.97% below its 50-day simple moving average ($14.69) and -7.19% below its 200-day simple moving average ($12.51). Across its 52-week range of $9.95 to $17.50, FRNM sits at the 22.0% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.16 to $13.06).

Direct Sub-Reports: FRNM RQD Cockpit FRNM 12M Forecast FRNM Earnings & Move FRNM Dividends & DRIP FRNM Insiders & 13F FRNM Whale Options FRNM Profit Sankey FRNM News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

FRNM — Freenome Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Freenome Inc. (FRNM) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $11.61 (-6.97% 1D, market capitalization $1.34B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -3.4%, gross margin of —, operating margin of —, and free cash flow yield of -0.06%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Freenome Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical Specialities industry. It operates in this industry with a market capitalization of $1.4B. Per the recent news wire, the company launched a lung cancer blood test positioned to make screening easier.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Freenome Inc. (FRNM) reported $8.3M in annual revenue (up from $37.8M in FY2024, -77.9% YoY) and $837.5K in GAAP net income. Over the multi-year SEC filing window from FY2024 ($37.8M revenue, $0 net income) through FY2025, FRNM scaled operating cash flow to -$864.7K and free cash flow to -$864.7K, backed by $92.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.06% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $9.95 – $17.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), FRNM carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can FRNM sustain or expand its — operating margin and -3.4% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $8.3M and free cash flow of -$864.7K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FRNM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FRNM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Freenome Inc. (FRNM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FRNM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FRNM Bull vs. Bear Conversation Board — What's Your Call at $11.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FRNM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FRNM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $14.48 (+16.0%)
📌 Pinned Debate

Recent news flow includes a reported 11% rise on the launch of a lung cancer blood test, a potential commercial catalyst.

Picked up a starter position in FRNM in my $100K Virtual Cash book at $12.48. Recent news flow includes a reported 11% rise on the launch of a lung cancer blood test, a potential commercial catalyst.. Trading inside a $9.95–$17.50 52-week range with -0.06% FCF yield gives solid downside support if Medical Specialities multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 5/20 institutional whale-flow stock at $12.48 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $10.36 (-17.0%)
Spot @ $12.48

ROIC of -3.4% and FCF yield of -0.06% show the business is not currently generating returns on invested capital.

Careful chasing FRNM at $12.48. ROIC of -3.4% and FCF yield of -0.06% show the business is not currently generating returns on invested capital.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $10.36 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%